UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of September, 2024.
Commission File Number: 001-40530
GH Research PLC
(Exact name of registrant as specified in its charter)
Joshua Dawson House
Dawson Street
Dublin 2
D02 RY95
Ireland
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
GH Research PLC (the “Company”) will attend the 37th ECNP Congress, which is scheduled to take place in Milan, Italy between September 21 – 24, 2024 (the “Congress”).
The Company will sponsor an industry mini session during the Congress.
A copy of the presentation prepared by Wieslaw J. Cubala to be delivered during the industry mini session is attached hereto as
Exhibit 99.1.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
GH Research PLC
|
|
Date: September 20, 2024
|
|
|
|
|
By:
|
/s/ Julie Ryan
|
|
Name:
|
Julie Ryan
|
|
Title:
|
Vice President, Finance
|
Exhibit 99.1
19/09/2024 1 Review of Ongoing Phase 2b Treatment-Resistant Depression Clinical
Trial (GH001-TRD-201) Wiesław J. Cubała Medical University of Gdańsk
Author Disclosure 19/09/2024 2 Conflict of interest statement regarding my
presentation in the ‘Industry session financially supported by GH Research during the 37th ECNP congress.’ Review of Ongoing Phase 2b TRD Clinical Trial (GH001-TRD-201) on 22 September 2024. I have an interest in relation to one or more
organisations that could be perceived as a possible conflict of interest in the context of the subject of this presentation. The relationships are summarised belowa: Interests Name of Organisation Grants Acadia, Angelini, Beckley Psytech,
GH Research, HMNC Brain Health, IntraCellular Therapies, Janssen, MSD, Novartis, Otsuka, Recognify Life Sciences Honoraria Angelini, Janssen, Novartis Shares - Paid positions Professor of Psychiatry (full-time), Medical University of
Gdańsk, Poland Advisory boards Douglas Pharmaceuticals, GH Research, Janssen, MSD, Novartis Other involvement - a Relationships reported within the last three years.
19/09/2024 3 A synthetic formulation of the serotonergic psychedelic
mebufotenina,b administered via pulmonary inhalation Rapid onset (within seconds) and short duration (<30mins) of psychoactive effects Single-dose administration OR an individualized dosing regimen (IDR) with up to three escalating doses
administered on a single day; escalation guided by peak experiencec No additional structured psychological support visits before or after dosing in clinical trial protocol GH Research is also developing an intravenous formulation of
mebufotenin: GH002 Abbreviations: PES = Peak experience scale. a Mebufotenin is not currently authorized as a treatment for any therapeutic indications. b Mebufotenin is more commonly known as 5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine). c
Peak experience is defined as achieving a score of ≥75 on the proprietary PES. 1. Reckweg JT, et al. Eur Psychiatry. 2022;65(supple 1):S716. 2. Reckweg JT, et al. Front. Psychiatry. 2023;14:1133414. doi: 10.3389/fpsyt.2023.1133414. Overview
of GH001 Clinical Trial Aspects1,2
19/09/2024 4 Two Phase 1 trials in HV (GH001-HV-101, GH001-HV-103) One Phase
1/2 trial in patients with TRD (GH001-TRD-102) 78 subjects dosed to date (completed studies only; 62 HV, 16 TRD) Three completed trials Four ongoing trials Phase 1 trial in HV (GH001-HV-106-2) using GH Research’s proprietary aerosol
delivery device Phase 2b trial in patients with TRD (GH001-TRD-201) Phase 2a trial in patients with bipolar II disordera (GH001-BD-202) Phase 2a trial in patients with PPD (GH001-PPD-203) GH002 (Intravenous) Completed trial One Phase 1
trial in HV (GH002-HV-105) 50 subjects dosed with GH002 to date Abbreviations: HV = Healthy volunteers; PPD = Postpartum depression; TRD = Treatment-resistant depression. a Patients must be diagnosed with bipolar II disorder with a current
major depressive episode. 1. Reckweg JT, et al. Eur Psychiatry. 2022;65(supple 1):S716. 2. GH Research, Data on file. 3. Reckweg JT, et al. Front. Psychiatry. 2023;14:1133414. doi: 10.3389/fpsyt.2023.1133414. Development Program
Status1-3 GH001 (Inhaled)
GH001 Single Dose: Inter-Person Variability GH001 IDR:Maximization of
Ultra-Rapid and Durable Remissions MADRS score MADRS score MADRS score MADRS score Dose 1 Dose 1 Dose 2 Dose 3 Dose 2 Dose 1 No remission Remissiona Remissiona Remissiona Remissiona Hypothetical Patient 1 Hypothetical
Patient 2 Hypothetical Patient 3 Hypothetical Patient 1 Hypothetical Patient 2 No remission No remission No remission Dose 1 MADRS score Dose 1 19/09/2024 5 Abbreviations: IDR = Individualized dosing regimen; MADRS =
Montgomery-Åsberg Depression Rating Scale; PE = Peak experience; PsE = Psychoactive effects. a Remission defined as a MADRS score ≤10. 1. Reckweg JT, et al. Eur Psychiatry. 2022;65(supple 1):S716. 2. Reckweg JT, et al. Front. Psychiatry.
2023;14:1133414. doi: 10.3389/fpsyt.2023.1133414. Utilization of IDR Dose Escalations to Maximize Therapeutic Response1,2
20/09/2024 6 Safety and Tolerability of GH001 in Completed
TrialsGH001-HV-1011, GH001-HV-1032, and GH001-TRD-1023 Safety Parameters, n Overall Population N=78 Any TEAE, n 50 Headache, no. of events 19 Anxiety, no. of events 12 Nausea, no. of events 8 Fatigue, no. of events 7 Any
Serious AE 0 Any AE leading to trial/drug withdrawal 0 Death 0 TEAEs by Severity, no. of events Overall Population N=78 Total number of TEAEs 105 Mild TEAEs 97 Moderate TEAEs 8 Severe TEAEs 0 Abbreviations: AE = Adverse
event; TEAE = Treatment-emergent adverse event. 1. Reckweg JT, et al. Eur Psychiatry. 2022;65(supple 1):S716. 2. GH Research, Data on file. 3. Reckweg JT, et al. Front. Psychiatry. 2023;14:1133414. doi: 10.3389/fpsyt.2023.1133414.
Overall, inhalation of GH001 was well tolerated across completed trials with no severe or serious adverse events reported and with TEAEs observed in 64.1% of subjects Most TEAEs were mild in severity (92.4%) and resolved
spontaneously No noteworthy changes in vital signs were observed; transient increases in heart rate and blood pressure shortly after GH001 administration were not clinically significant Safety assessments, including laboratory analyses,
psychiatric scales, electrocardiogram, and cognitive function tests, showed no clinically meaningful changes
19/09/2024 7 Single Dose (Day 7) Individualized Dosing Regimen (Day 7) 2/4
(50%) patients in the 12 mg group and 1/4 (25%) in the 18 mg group had a MADRS remission at Day 7 2/8 patients had a PEc and both had a MADRS remission at Day 7 7/8 (87.5%) patients had a MADRS remission at Day 7 7/8 patients had a PEc and
6 of those had a MADRS remission at Day 7 a b a b Abbreviations: MADRS = Montgomery–Åsberg Depression Rating Scale; PE = Peak experience; PES = Peak experience scale. a Remission is defined as a patient achieving a MADRS score of ≤10
after dosing. b Response is defined as a patient achieving ≥50% reduction from baseline in MADRS total score after dosing. c PE is defined as achieving a score of ≥75 on the proprietary PES. 1. Reckweg JT, et al. Front. Psychiatry.
2023;14:1133414. doi: 10.3389/fpsyt.2023.1133414. Efficacy of GH001 GH001-TRD-1021
Hour 2 Day 1 Day
7 GH001 p=0.0018 p<0.0001 p<0.0001 Baselinea 19/09/2024 8 Efficacy of GH001 (MADRS Change from Baseline) GH001-TRD-102: Individualized Dosing Regimen1 Abbreviations: MADRS = Montgomery–Åsberg Depression Rating Scale. a Baseline
mean MADRS = 32. 1. Reckweg JT, et al. Front. Psychiatry. 2023;14:1133414. doi: 10.3389/fpsyt.2023.1133414.
19/09/2024 9 Abbreviations: D = Day; H = Hour; IDR = Individualized dosing
regimen; M = Month; MADRS = Montgomery–Åsberg Depression Rating Scale; OLE = Open-label extension; PRN = Pro re nata (as needed); TRD = Treatment-resistant depression. aThe double-blind phase was a fixed duration of 7 days (± 1 day) after an
IDR with visits on D0, D1 and D7. After the double-blind phase there was a variable duration until a potential GH001 IDR in the OLE. bDuring the OLE, additional clinic visits can be scheduled if required for medical reasons. cThe GH001 IDR
consists of up to 3 increasing doses (6, 12, 18 mg) and the placebo IDR consists of up to three placebo doses. As in previously completed trials, the GH001-TRD-201 trial will be conducted under the supervision of a healthcare provider, but
without any planned psychotherapeutic interventions before, during, or after dosing. 1. NCT05800860. (2024). A Trial of GH001 in Patients With Treatment-Resistant Depression. ClinicalTrials.gov. Accessed August 23, 2024.
https://clinicaltrials.gov/ct2/show/NCT05800860. GH001-TRD-201 Trial DesignPhase 2b trial in patients with TRD1 Baseline (H2) Double-Blind Phasea n=80 Randomization 1:1 GH001 IDRc Placebo IDRc Up to 5 GH001 IDRs may be administered
during the OLE PRN, based on specific re-treatment criteria Baseline (H2) Scheduled Visit D14 M1 M2 M3 M4 M5 M6 MADRS assessment D0 D1 D7 D1 D0 Primary Endpoint ΔMADRS D7 Open-Label Extension Phaseb PRN
Thank you for your attention! 19/09/2024 10
